| scholarly article | Q13442814 |
| P50 | author | Benjamin M. Davis | Q42328318 |
| Satyanarayana Somavarapu | Q90428218 | ||
| P2093 | author name string | Giulia Malaguarnera | |
| Li Guo | |||
| M Francesca Cordeiro | |||
| Parth Shah | |||
| Milena Pahlitzsch | |||
| Nivedita Ravindran | |||
| Claudia Sisa | |||
| Ehtesham Shamsher | |||
| Acom Sornsute | |||
| Abdinasir Noor | |||
| Hisham Hamze | |||
| Shiama Balendra | |||
| P2860 | cites work | Ranibizumab and bevacizumab for neovascular age-related macular degeneration | Q24616209 |
| Targeting amyloid-beta in glaucoma treatment. | Q24681763 | ||
| Current perspective of neuroprotection and glaucoma | Q26774852 | ||
| The chemistry of curcumin: from extraction to therapeutic agent | Q26852753 | ||
| Glaucoma: the retina and beyond | Q28077518 | ||
| Bioavailability of curcumin: problems and promises | Q28257125 | ||
| Pharmacology of Curcuma longa | Q28328461 | ||
| Curcumin inhibits neuronal and vascular degeneration in retina after ischemia and reperfusion injury | Q28476485 | ||
| Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo | Q29619108 | ||
| Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus | Q30884984 | ||
| Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes | Q31013452 | ||
| Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study | Q33230568 | ||
| Hyperbaric pressure and increased susceptibility to glutamate toxicity in retinal ganglion cells in vitro | Q33461601 | ||
| Real-time imaging of single neuronal cell apoptosis in patients with glaucoma. | Q33729892 | ||
| Inducible nitric oxide synthase-mediated alteration of mitochondrial OPA1 expression in ocular hypertensive rats | Q33789800 | ||
| Lutein protects RGC-5 cells against hypoxia and oxidative stress | Q33910891 | ||
| Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | Q33956003 | ||
| Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers | Q34066706 | ||
| Towards maximising information extraction from rodent models of ocular disease. | Q42136792 | ||
| Label-free critical micelle concentration determination of bacterial quorum sensing molecules. | Q42183254 | ||
| Automatic quantitative analysis of experimental primary and secondary retinal neurodegeneration: implications for optic neuropathies | Q42368091 | ||
| Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. | Q42379723 | ||
| Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head | Q42635765 | ||
| Cytoprotective effects of vitamin E homologues against glutamate-induced cell death in immature primary cortical neuron cultures: Tocopherols and tocotrienols exert similar effects by antioxidant function. | Q42927207 | ||
| Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients. | Q43026393 | ||
| PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes | Q43088170 | ||
| Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma | Q43111984 | ||
| Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery | Q43610585 | ||
| Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. | Q43670860 | ||
| Improved HPLC method for the determination of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. | Q44023968 | ||
| Formation and stabilisation of triclosan colloidal suspensions using supersaturated systems | Q44524000 | ||
| A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. | Q44526862 | ||
| Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance | Q45122000 | ||
| Critical role of Nrf2 in oxidative stress-induced retinal ganglion cell death. | Q45391363 | ||
| Muscarinic activation attenuates abnormal processing of beta-amyloid precursor protein induced by cobalt chloride-mimetic hypoxia in retinal ganglion cells. | Q46037591 | ||
| Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. | Q46098774 | ||
| Curcumin inhibits hypoxia inducible factor‑1α‑induced epithelial‑mesenchymal transition in HepG2 hepatocellular carcinoma cells | Q46115977 | ||
| Glutamate excitotoxicity is involved in cell death caused by tributyltin in cultured rat cortical neurons | Q46738347 | ||
| Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer's disease model via canonical Wnt/β-catenin pathway | Q46812187 | ||
| Biotransformation of curcumin through reduction and glucuronidation in mice | Q48249491 | ||
| Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects | Q34069410 | ||
| A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes | Q34122290 | ||
| The applications of Vitamin E TPGS in drug delivery | Q34332636 | ||
| Whole number, distribution and co-expression of brn3 transcription factors in retinal ganglion cells of adult albino and pigmented rats. | Q34482813 | ||
| Current understanding of neuroprotection in glaucoma | Q34553234 | ||
| Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma | Q34582504 | ||
| Curcumin/turmeric solubilized in sodium hydroxide inhibits HNE protein modification--an in vitro study | Q34583102 | ||
| The role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARγ in retinal neuroprotection | Q34851916 | ||
| Recent advances of chitosan nanoparticles as drug carriers | Q34956317 | ||
| Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles | Q36148565 | ||
| Possible role of excitotoxicity in the pathogenesis of glaucoma | Q36383884 | ||
| Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin | Q36458029 | ||
| Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors | Q36496079 | ||
| Therapeutic roles of curcumin: lessons learned from clinical trials | Q36502400 | ||
| Degradation of Curcumin: From Mechanism to Biological Implications | Q36576123 | ||
| Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. | Q36701086 | ||
| Hypoxia inducible factor-1α (HIF-1α) and some HIF-1 target genes are elevated in experimental glaucoma | Q36728977 | ||
| Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1β via suppressing astroglial NALP1 inflammasome and JAK2-STAT3 signalling | Q37067714 | ||
| Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review | Q37443524 | ||
| Alpha-tocopherol: looking beyond an antioxidant | Q37458194 | ||
| Review: R28 retinal precursor cells: the first 20 years | Q37639375 | ||
| Curcuminoids in neurodegenerative diseases. | Q38022283 | ||
| Oxidative stress and mitochondrial dysfunction in glaucoma | Q38052297 | ||
| Nanocrystals for the parenteral delivery of poorly water-soluble drugs | Q38104343 | ||
| Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. | Q38224185 | ||
| Mitochondria as a target in the therapeutic properties of curcumin. | Q38253091 | ||
| Neuroprotective effect of curcumin against oxidative damage in BV-2 microglia and high intraocular pressure animal model | Q38981384 | ||
| Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes | Q39018489 | ||
| Unexpected low-dose toxicity of the universal solvent DMSO. | Q39044534 | ||
| Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas | Q39324149 | ||
| A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells | Q39518087 | ||
| Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis | Q39676512 | ||
| Topical ocular drug delivery: recent developments and future challenges | Q39702826 | ||
| Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model | Q41916614 | ||
| α-Tocopherols modify the membrane dipole potential leading to modulation of ligand binding by P-glycoprotein | Q42026315 | ||
| Therapeutic Retrobulbar Inhibition of STAT3 Protects Ischemic Retina Ganglion Cells. | Q51040094 | ||
| Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation. | Q54839313 | ||
| DFT and experimental studies of the structure and vibrational spectra of curcumin | Q56441845 | ||
| Retinal Damage Caused by High Intraocular Pressure–Induced Transient Ischemia is Prevented by Coenzyme Q10 in Rat | Q61897001 | ||
| A rat model of chronic pressure-induced optic nerve damage | Q73202589 | ||
| Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group | Q77436645 | ||
| Risk factors for incident open-angle glaucoma: the Barbados Eye Studies | Q80608143 | ||
| Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye | Q80653757 | ||
| Use of curcumin to decrease nitric oxide production during the induction of antitumor responses by IL-2 | Q83389870 | ||
| PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms | Q84608906 | ||
| Coenzyme Q10 vitreous levels after administration of coenzyme Q10 eyedrops in patients undergoing vitrectomy | Q84620667 | ||
| Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution | Q93587010 | ||
| Brimonidine | Q94447141 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | eye disease | Q3041498 |
| nanocarrier | Q17153796 | ||
| P304 | page(s) | 11066 | |
| P577 | publication date | 2018-07-23 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease | |
| P478 | volume | 8 |
| Q92629828 | Curcumin as a Therapeutic Option in Retinal Diseases |
| Q91656644 | Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers |
| Q91858777 | Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review |
| Q64997207 | Nutraceuticals for the Treatment of Diabetic Retinopathy. |
| Q91936690 | Retinal correlates of neurological disorders |
Search more.